| Literature DB >> 30629576 |
Shahla M Jilani, Meghan T Frey, Dawn Pepin, Tracey Jewell, Melissa Jordan, Angela M Miller, Meagan Robinson, Tomi St Mars, Michael Bryan, Jean Y Ko, Elizabeth C Ailes, Russell F McCord, Julie Gilchrist, Sarah Foster, Jennifer N Lind, Lindsay Culp, Matthew S Penn, Jennita Reefhuis.
Abstract
From 2004 to 2014, the incidence of neonatal abstinence syndrome (NAS) in the United States increased 433%, from 1.5 to 8.0 per 1,000 hospital births. The latest national data from 2014 indicate that one baby was born with signs of NAS every 15 minutes in the United States (1). NAS is a drug withdrawal syndrome that most commonly occurs among infants after in utero exposure to opioids, although other substances have also been associated with NAS. Prenatal opioid exposure has also been associated with poor fetal growth, preterm birth, stillbirth, and possible specific birth defects (2-5). NAS surveillance has often depended on hospital discharge data, which historically underestimate the incidence of NAS and are not available in real time, thus limiting states' ability to quickly direct public health resources (6,7). This evaluation focused on six states with state laws implementing required NAS case reporting for public health surveillance during 2013-2017 and reviews implementation of the laws, state officials' reports of data quality before and after laws were passed, and advantages and challenges of legally mandating NAS reporting for public health surveillance in the absence of a national case definition. Using standardized search terms in an online legal research database, laws in six states mandating reporting of NAS from medical facilities to state health departments (SHDs) or from SHDs to a state legislative body were identified. SHD officials in these six states completed a questionnaire followed by a semistructured telephone interview to clarify open-text responses from the questionnaire. Variability was found in the type and number of surveillance data elements reported and in how states used NAS surveillance data. Following implementation, five states with identified laws reported receiving NAS case reports within 30 days of diagnosis. Mandated NAS case reporting allowed SHDs to quantify the incidence of NAS in their states and to inform programs and services. This information might be useful to states considering implementing mandatory NAS surveillance.Entities:
Mesh:
Year: 2019 PMID: 30629576 PMCID: PMC6342546 DOI: 10.15585/mmwr.mm6801a2
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Legislation mandating neonatal abstinence syndrome (NAS) case reporting — six states, 2013–2017
| State | Citation | Effective year | Is there a definition of NAS used in the law? | Who must report NAS? | To whom must NAS be reported? | Time frame for reporting to | |||
|---|---|---|---|---|---|---|---|---|---|
| Provider/Facility* | Dept. of Health | Dept. of Health | Legislative body | Dept. of Health | Legislative body | ||||
| Arizona | AZ. Admin. code § R9–4-602 | 2017 | No | Yes | — | Yes | — | 5 business days | N/A |
| Florida | 2014 | No | Yes | — | Yes | — | 6 months† | N/A | |
| Georgia | GA. Code Ann. § 31–12–2 | 2017 | Yes§ | Yes | Yes¶ | Yes | Yes | N/A** | annually |
| Kentucky | KY. Rev. Stat. Ann. § 211.676 | 2013 | No | Yes | — | Yes | — | at time of diagnosis | N/A |
| KY. Rev. Stat. Ann. § 211.678 | 2014 | ||||||||
| Tennessee†† | TN. Code Ann. § 68–1-805 | 2017 | No | — | Yes | — | Yes | N/A | annually |
| Virginia§§ | 12 VA. Admin. Code § 5–90–80¶¶ | 2017 | Yes*** | Yes | — | Yes | — | 1 month | N/A |
Abbreviations: AZ = Arizona; FL = Florida; GA = Georgia; KY = Kentucky; N/A = not applicable; TN = Tennessee; VA = Virginia.
* Defines providers broadly to include coroners and medical examiners. Facilities are also defined broadly to include hospitals, birthing centers, and various healthcare facilities. Individual states might have laws with additional mandatory reporters. For example, see GA. Code Ann. § 31–12–2, in which “any other person or entity the department determines has knowledge of diagnosis or health outcomes related, directly or indirectly” must also report NAS.
† FL. Admin. Code Ann. r. 64D-3.029(3), FN 18. Within 6 months, hospitals must “report each case of neonatal abstinence syndrome occurring in an infant admitted to the hospital.” However, “[i]f a hospital reports a case of neonatal abstinence syndrome to the Agency for Health Care Administration in its inpatient discharge data report, pursuant to Chapter 59E-7, F.A.C., then it need not comply with the reporting requirements of subsection 64D-3.029(1), F.A.C.”
§ GA. Code Ann. 31–12–2. “’[N]eonatal abstinence syndrome’ means a group of physical problems that occur in a newborn infant who was exposed to addictive illegal or prescription drugs while in the mother’s womb.”
¶ The Georgia Department of Health must report NAS case load and NAS incidence to the state legislature on a yearly basis.
** GA. Code Ann. 31–12–2 indicates that reporting shall take place “in a manner and at such times as may be prescribed.” The health department has used this authority to require a 30-day time frame for reporting.
†† See also Tenn. Comp. R. and Regs. 1200–14–01-.02 (2010). This law does not use the terminology “neonatal abstinence syndrome” but does authorize the health commissioner to add diseases to the reportable disease list, which requires providers to report to the state health department. Tennessee added NAS to its reportable disease list in 2013.
§§ See also VA Code Ann. § 32.1–35 (West 2018). This law does not use the terminology “neonatal abstinence syndrome” but does authorize the board to add diseases to the reportable disease list. NAS is on the reportable disease list in Virginia.
¶¶ Virginia’s legislature enacted an uncodified act (SB1323/HB1467) Acts 2017, mL. 185 and 280, requiring the Board of Health to adopt regulation to include NAS as a reportable disease.
*** 12 VA Admin Code 5–90–80. “[A] condition characterized by clinical signs of withdrawal from exposure to prescribed or illicit drugs.”
Advantages and challenges of surveillance features reported by health officials among states with mandated reporting of neonatal abstinence syndrome (NAS) — six states, 2013–2017
| Surveillance feature reported in 28-item questionnaire | States endorsing surveillance feature in questionnaire | Advantages (+) and challenges (-) reported by health officials in open-text fields in questionnaire and during semistructured interviews |
|---|---|---|
|
| ||
| Clinical diagnoses by medical provider* | AZ, FL, GA, KY, TN, VA | – Requires additional review to identify duplicate NAS cases (i.e., if infant is treated at multiple facilities or at delivery and at another encounter postdischarge) |
| – Providers might look to state health departments for a case definition | ||
| – Will not identify asymptomatic infants with prenatal substance exposure | ||
| – Transition from | ||
| Positive toxicology result for infant | GA† | + Toxicology results allow state to determine whether substance exposure was from a prescribed medication or an illicit substance§ |
|
| ||
| Maternal demographics | FL, GA, KY, TN | + Allows for characterizations of populations at higher risk and areas of higher risk |
| Infant demographics | AZ, FL, GA, KY, TN, VA | + Opportunity to identify patterns in specific geographic areas |
| Maternal source of exposure(s) | AZ, GA, KY, TN, VA | + Can identify prenatal exposures |
| + Allows for comparison between clinical symptoms of withdrawal and substance exposure in the absence of clinical symptoms of withdrawal | ||
| + Provides information on polysubstance exposures | ||
| Heath care service utilization by infant | GA | + Ability to estimate costs associated with treatment |
| + Can capture characteristics of treatment (e.g., length of stay) | ||
| Other | AZ, GA, KY, TN | + Some variables (e.g., medical record number) allows for linkage with other data sources |
| Clinical signs and symptoms | ||
| Substances for which mother/infant tested positive | ||
| Maternal use of medication-assisted treatment | ||
| Maternal history of substance misuse | ||
|
| ||
| State had an existing notifiable disease surveillance system | AZ, GA, VA | + Existing in-house system allows for more rapid changes to reporting system to be implemented |
| + More timely reporting | ||
| – Obstetric and neonatal providers might not be familiar with case reporting because many notifiable conditions are for infectious diseases | ||
| State has hospital discharge data linked to vital records | FL | + Ability to link to other vital records and public health surveillance systems |
| + Feasible in the absence of funding resources | ||
| – Coding errors | ||
| – Might not capture infants delivered or treated outside of a hospital setting | ||
| – Does not consistently capture specific substance exposures | ||
| – Duplications in reported cases if infant is transferred | ||
| – Deidentified data does not allow for referrals to services | ||
| State has NAS-specific reporting system | KY, TN, VA | + Might allow for online case reporting |
| + Case report form can be easily modified | ||
| + Reduces need for additional resources required by paper-based system (e.g., data entry) | ||
| – Online reporting system might require system maintenance | ||
|
| ||
| Data completeness | FL, GA, KY | + Required reporting elements can reduce number of missing values |
| – Delays in laboratory reports can lead to missing toxicology data | ||
| – Lack of clinical case definition can lead to differences in variables reported by provider | ||
|
| ||
| Educating providers/hospitals about reporting requirements | GA, KY, TN, VA | – Added responsibility for medical provider and hospital staff members |
| Collecting missing data | AZ, GA | – Requires fiscal and human resources to collect missing data and to train staff members to input data and review records |
| Other | FL, KY | – Requires fiscal and human resources |
| Data cleaning | ||
| Data reporting | ||
|
| ||
| Identification of women with substance use disorder | AZ | + Opportunity to link women to treatment |
| Identification of mothers with multiple pregnancies affected by opioid exposure | FL | + Opportunity for prevention of future NAS cases |
| Shared with other state and local agencies | GA, FL, KY, TN | + Informs community assessments, planning, and program development |
| + Opportunity to evaluate the incidence of NAS within the state | ||
| + Informs interventions | ||
| Public reporting (as of March 2018) | AZ, GA, KY, TN | + Opportunity to inform partners |
|
| ||
| Limited awareness of mandate | GA | – Underreporting from providers might underestimate incidence of NAS |
| Limitations at the hospital/provider level | AZ, GA, KY, TN, VA | – Hospital staff member turnover can create reporting gaps/underreporting |
| – Training new staff members in reporting process | ||
| – Providers might have limited knowledge of reporting criteria | ||
| – Complexity of reporting form | ||
Abbreviations: AZ = Arizona; FL = Florida; GA = Georgia; KY = Kentucky; TN = Tennessee; VA = Virginia.
* During interviews the benefits of having a clinical diagnosis by a medical provider as part of the case definition were not specifically discussed.
† In Georgia, infants with a clinical diagnosis of NAS or a positive toxicology result should be reported to the state health department.
§ Toxicology results do not provide information on whether a prescribed substance was used as prescribed or diverted.